<DOC>
	<DOCNO>NCT02218125</DOCNO>
	<brief_summary>The purpose study assess safety tolerability Modified Vaccinia Ankara ( MVA ) Mosaic vaccine healthy adult participant .</brief_summary>
	<brief_title>A Phase I Study HIV Vaccine Healthy , HIV Uninfected Adults</brief_title>
	<detailed_description>This Phase I , placebo-controlled ( use inactive substance identical appearance active vaccine ) , double-blind ( neither participant study personnel know identity treatment administer ) study participant randomize ( treatment type assign chance ) receive Modified Vaccinia Ankara ( MVA ) Mosaic vaccine ( 1x10E8 pfu ) placebo . This design intend reduce likelihood observer selection bias , provide control confound variable , aid unbiased analysis study result . The study include 4 group participant , 2 group previously vaccinate Ad26.ENVA.01 ( A recombinant adenovirus [ rAd ] vaccine HIV-1 ) 2 group previously vaccinate Ad26.ENVA.01 . Participants randomize 4:1 ratio receive either MVA Mosaic vaccine placebo . The trial comprise 4-week screening period , 12-week vaccination period participant vaccinate baseline ( Day 1 ) Week 12 ( Day 84 ) , 40-week follow-up period final visit Week 52 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult ( determined medical history , physical examination , clinical judgment ) HIV uninfected Female participant child bear potential must negative serum Î²human chorionic gonadotrophin pregnancy test screen visit immediately prior vaccine/placebo administration , practice adequate birth control measure 28 day prior first vaccine/placebo administration least 3 month final vaccine/placebo administration Male participant sexually active woman childbearing potential vasectomy must agree use double barrier method birth control , e.g . either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository Confirmed HIV1/2 infection Chronic active hepatitis B hepatitis C active syphilis infection . Active syphilis document exam serology unless positive serology due past treated infection Within 12 month prior enrollment : history newly acquire syphilis , gonorrhea , nongonococcal urethritis , herpes simplex virus type 2 ( HSV2 ) , Chlamydia , pelvic inflammatory disease ( PID ) , trichomonas , mucopurulent cervicitis , epididymitis , proctitis , lymphogranulomavenereum , chancroid , hepatitis B A woman breastfeed Any clinically significant acute chronic medical condition , opinion investigator , would preclude participation Major surgery within 4 week prior study entry plan major surgery course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Human immunodeficiency virus type 1 ( HIV-1 ) infection</keyword>
	<keyword>Acquired immunodeficiency syndrome ( AIDS )</keyword>
	<keyword>recombinant adenovirus ( rAd ) vector-based vaccine</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Ad26.ENVA.01</keyword>
	<keyword>Recombinant</keyword>
	<keyword>Modified Vaccinia Ankara ( MVA ) vector-based vaccine</keyword>
</DOC>